BUZZ-Australia's Neurizon Therapeutics slides after FDA puts drug application on hold

Shares of Neurizon Therapeutics NUZ.AX fall 26.5% to A$0.125, their lowest level since Jan. 15, 2024

Stock falls as much as 29.4% in its biggest intraday pct drop since early September 2020

Biotech firm receives notification from the U.S. FDA that its investigational new drug (IND) application for NUZ-001 to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, has been put under clinical hold

IND application is a request for authorisation to administer experimental drugs to humans

Co says FDA has outlined certain concerns over sufficiency of information to assess application

More than 2.9 mln shares change hands, 7.1 times the 30-day avg

Neurizon down 26.5% YTD, including current session's moves

(Reporting by Nikita Maria Jino in Bengaluru)

((Nikita.Jino@thomsonreuters.com;))